9 min. read

20 percent of Rx-only digital therapeutics have studies so far.

Issue 065.



Get E&O weekly. | Subscribe

Digital health research from Brian Dolan.

Welcome to E&O.

Last week I wrote about Teladongo, no bids for Proteus, and a pretty lengthy list of digital health-related CPT codes that the AMA's editorial panel is set to consider in October. Here's what's happening this week:

  • I'm working on a long-form report focused on Evidation Health. Any insights, metrics, rumors you can share? What would you like to better understand about Evidation? Hit reply to send me tips and questions.
  • Also, last week -- about an hour after I send the newsletter -- the AMA broke the link to its list of potential CPT codes. Here's a working link, which they updated seemingly because of a copy-paste error. (This new URL will likely break once they make an edit in September since -- mindbogglingly -- their URLs use a numeral to denote the month.)
  • The Lazarus of Digital

Paying Subscribers Only

It's a good one, too.
This digital health research is for paying Exits & Outcomes subscribers only. Subscribe now to read this article, get the weekly newsletter, and receive unrestricted access to past and future research from the Exits & Outcomes archives. Smash the link above or below to subscribe yourself -- or head over to our pricing page to subscribe your team or your whole company!

Recent Articles